| Cardiovascular disease (CVD) is one of the leading | | | | cardiac testing |
| causes of death in the developed world, accounting | | | | • Identify the novel imaging technologies and |
| for around a third of all deaths. It remains a | | | | instruments that may revolutionize cardiovascular |
| tremendous medical and cost burden on society. The | | | | imaging, including the development of 124 and 245 |
| identification and application of novel cardio biomarkers | | | | multislice CT, hybrid systems (PET-CT, SPECT-CT |
| has helped cardiologists to stratify high risk patients | | | | and the development of highly portable and |
| whilst the advances in diagnostic imaging has lead to | | | | miniaturized ECG and US equipment. |
| improvements in the speed and resolution of images, | | | | Scope of this report |
| increasing its clinical utility in the detection, diagnosis and | | | | • Identify key technologies for IVD and diagnostic |
| treatment of CVD whilst minimizing the need for | | | | imaging and their applications in early diagnosis, |
| invasive procedures. In addition, diagnostic imaging | | | | treatment and patient monitoring of a range of |
| provides cardiologists with detailed anatomical (CT, | | | | cardiovascular diseases |
| MRI, US), metabolic and functional (nuclear imaging, | | | | • Identify the companies leading the field in |
| fMRI) information upon which an accurate diagnosis an | | | | developing novel technologies for IVD and diagnostic |
| be made. Currently no single imaging test is superior to | | | | imaging |
| all the others and a variety of imaging modalities may | | | | • Discover the approaches being adopted by the |
| be used to diagnose CVD. | | | | leading IVD and healthcare companies |
| A variety of cardiac biomarkers are now available | | | | • Discover the potential of these products and |
| including those to determine cholesterol & | | | | technologies for improving diagnosis and guiding |
| lipoproteins levels, cardiac necrosis, thrombosis, | | | | treatment decisions earlier during the course of |
| inflammation and genetic variants - to aid in patient risk | | | | cardiovascular disease process to help to reduce |
| stratification and the diagnosis of a range of | | | | long-term healthcare costs |
| cardiovascular conditions – acute coronary | | | | Key Market Issues |
| syndrome (ACS), coronary artery disease (CAD), | | | | • Improving diagnosis: Increasingly, IVD testing is |
| heart failure (HF), stroke and pulmonary embolism (PE). | | | | being used by cardiologist in conjunction with diagnostic |
| A raft of possible and probable cardiac biomarkers | | | | imaging to stratify patient risk, to improve diagnosis, |
| are currently under evaluation that if successful, may | | | | minimize the use of invasive procedures, and improve |
| provide cardiologist with a more comprehensive | | | | patient management. |
| assessment of cardiovascular risk and prognosis. | | | | • IVD testing to identify patient predisposed to |
| Meanwhile in vitro diagnostic (IVD) companies have | | | | disease and to determine prognosis: Several tests are |
| launched a range of assay platforms including | | | | now available that can indentify asymptomatic patients |
| laboratory bases ultra high through systems to point of | | | | that are at high risk of CV disease allowing for early |
| care (PoC) bench top and hand held devices. Enabling | | | | dietary and lifestyle interventions and the prescription |
| rapid and cost-effective testing and migrating CV | | | | of preventative medicine if necessary, in addition |
| testing from the hospital to the clinic and bedside. | | | | prognostic tests following MI are available to help guide |
| Key features of this report | | | | cardiologist for the most appropriate long-term |
| • Highlight some of the key technologies which IVD | | | | therapeutic or surgical intervention helping to minimizing |
| and healthcare companies are developing to maximize | | | | future risk. |
| the using of medical imaging in the detection and | | | | • Innovative opportunities: Molecular imaging is one |
| diagnosis of cardiovascular diseases | | | | of the most rapidly evolving areas of medical imaging |
| • Analysis the recent advances in cardiac | | | | and has application in drug R&D and clinical |
| biomarker discovery and validation and their potential | | | | diagnostics. Molecular imaging can be applied in the |
| application as single or multimarket tests in the clinic | | | | clinical setting molecular imaging probes may be used |
| and emergency department. | | | | as surrogate endpoints to assess new treatments or |
| • Discuss the shift in the decentralization of cardiac | | | | monitor the effect of therapy for a variety of |
| diagnostics from the laboratory based testing to PoC | | | | diseased states, leading to developmental cost-savings |
| testing in the emergency room due to advances in | | | | through the rapid accumulation of clinical evidence to |
| biosensor and the adoption of wireless technology and | | | | support drug approval and usage. |
| leading to improvements in the speed and cost of | | | | |